What is Cytomos?
Cytomos specializes in high-throughput cell analysis, providing innovative solutions that address persistent bottlenecks in bioprocessing. Through its proprietary AuraCyt and Celledonia systems, the company delivers rapid, data-rich insights that are essential for modern cell line development and bioprocess optimization. By streamlining these complex workflows, Cytomos empowers organizations involved in monoclonal antibody production, viral vector manufacturing, and advanced cell therapies to reduce operational costs and shorten time-to-market. The company's market position is defined by its ability to bridge the gap between traditional laboratory analysis and the high-speed requirements of industrial-scale biomanufacturing, making it a vital partner for firms seeking to enhance efficiency in the rapidly evolving biotechnology ecosystem.
How much funding has Cytomos raised?
Cytomos has raised a total of $13.3M across 3 funding rounds:
Angel/Seed
$1.9M
Other Financing Round
$5M
Other Financing Round
$6.3M
Angel/Seed (2022): $2M with participation from Old College Capital and Scottish Enterprise
Other Financing Round (2023): $5M led by Archangels, British Business Bank, Old College Capital, and Scottish Enterprise
Other Financing Round (2024): $6.4M supported by Archangel Capital Partners, Edinburgh Innovations, Scottish Enterprise, and British Business Bank
Key Investors in Cytomos
Scottish Enterprise
A national economic development agency and non-departmental public body of the Scottish Government, focused on fostering innovation and economic growth.
British Business Bank
A government-owned development bank dedicated to increasing the supply of credit and financial support to small and medium-sized enterprises.
Edinburgh Innovations
The commercialization arm of the University of Edinburgh, specializing in technology transfer, consultancy, and collaborative research to bring academic innovation to the marketplace.
What's next for Cytomos?
With the successful closure of this major strategic investment, Cytomos is poised to enter a new phase of commercial expansion and technological refinement. The company is expected to leverage this capital to broaden its reach within the cell therapy and bioprocessing markets, focusing on the integration of its analytical tools into larger-scale industrial workflows. As the demand for rapid, actionable data in drug development continues to rise, Cytomos will likely prioritize the scaling of its manufacturing capabilities and the expansion of its commercial team. By maintaining its focus on reducing development cycles, the firm is strategically aligned to capture significant market share, ultimately driving long-term value for its stakeholders and advancing the efficiency of global bioprocessing standards.
See full Cytomos company page
